In this context, preliminary results of an ongoing clinical study (ByLieve), recruiting patients with advanced HR+/HER2-, PIK3CA-mutant breast cancers who have had disease progression during or after a CDK4/6 inhibitor, have shown a rate of response that was comparable to that observed in the context of SOLAR-1 study [375]. Here, ERBB2 is linked to breast cancer.